ranolazine

Ranolazine (RS 43285-003) is a calcium uptake inhibitor via the sodium/calcium channel, used to treat chronic angina. It affects the sodium-dependent calcium channels during myocardial ischemia in rabbits by altering the intracellular sodium level.

Ranolazine dihydrochloride (Ranolazine 2HCl) , an antianginal agent, can treat arrhythmia via a novel mechanism of action (inhibition of the late phase of the inward sodium current), and do not affect blood pressure or heart rate.

Desmethyl ranolazine is a metabolite of the antianginal agent ranolazine .1It is formed from ranolazine by the cytochrome P450 (CYP) isoform CYP3A. 1.Wang, Y., Chen, X., Sun, Z., et al.Development and validation of a sensitive LC-MS/MS assay for simultaneous quantitation of ranolazine and its three metabolites in human plasmaJ. Chromatogr. B889-89010-16(2012)

Desmethyl ranolazine β-D-glucuronide is a biochemical reagent used in glycobiology research. Glycobiology explores the structure, synthesis, biology, and evolution of sugars. This field covers carbohydrate chemistry, enzymology of glycan formation and degradation, protein-glycan interactions, and the function of glycans in biological systems. It is closely linked to fundamental research, biomedicine, and biotechnology.

CVT-2738 (RS-94287) is a metabolite of Ranolazine. Ranolazine is a partial fatty acid oxidation (pFOX) inhibitor and anti-anginal drug.